BL Laube, RM Auci, DE Shields, DH Christiansen, MK Lucas, HJ Fuchs and BJ Rosenstein
Department of Environmental Health Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

We tested the hypothesis that recombinant human deoxyribonuclease 1 (rhDNase) reduces airflow obstruction and improves mucociliary clearance in patients with cystic fibrosis (CF), and that improvements seen in FEV1 and FVC after rhDNase treatment are independent of chest physical therapy (CPT). CF patients inhaled placebo (10 patients) or 2.5 mg rhDNAse aerosol (10 patients) twice a day for six consecutive days. Compared with baseline, there were no statistically significant differences between the two study groups by Day 6 for indices of airflow obstruction obtained from gamma-camera images of the right lung following inhalation of 99mTc aerosol, or for mucociliary clearance or the rate of clearance of the radioaerosol, quantified over a 6-h period. By Day 6, FEV1 and FVC were significantly higher in the rhDNase- treated group than in the placebo group, increasing by an average of 9.4 +/- 3.5% and 12.7 +/- 2.6%, respectively, as compared with a decrease of 1.8 +/- 1.7% and an increase of 0.4 +/- 1.1%, respectively (p < 0.05). There was no significant change in the FEV1/FVC ratio on Day 6 (0.68 +/- 0.05) compared with baseline (0.70 +/- 0.05) in the rhDNase group. On Day 6, FEV1 and FVC decreased after CPT in both study groups, but the decreases were not significant. Our results indicate that aerosolized rhDNase improves FEV1 and FVC independent of CPT. We were unable to demonstrate that rhDNase reduces airflow obstruction or improves mucociliary clearance.

This article has been cited by other articles:

				P. A. Flume, B. P. O'Sullivan, K. A. Robinson, C. H. Goss, P. J. Mogayzel Jr., D. B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 957 - 969. [Abstract] [Full Text] [PDF]

				S. H. Donaldson, T. E. Corcoran, B. L. Laube, and W. D. Bennett Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research Proceedings of the ATS, August 1, 2007; 4(4): 399 - 405. [Abstract] [Full Text] [PDF]

				S. McGrath-Morrow, B. Laube, S.-C. Tzou, C. Cho, J. Cleary, H. Kimura, N. R. Rose, and P. Caturegli IL-12 overexpression in mice as a model for Sjogren lung disease Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L837 - L846. [Abstract] [Full Text] [PDF]

				I. Aziz, J. A. Kastelik, S. Zarogiannis, C. Hatzoglou, K. Gourgoulianis, R. Kuver, S. P. Lee, P. T.P. Bye, M. R. Elkins, S. H. Donaldson, et al. Hypertonic saline for cystic fibrosis. N. Engl. J. Med., April 27, 2006; 354(17): 1848 - 1851. [Full Text] [PDF]

				D. C. Bolser Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 238S - 249S. [Abstract] [Full Text] [PDF]

				E. M. Raynor, A. Butler, M. Guill, and J. P. Bent III Nasally Inhaled Dornase Alfa in the Postoperative Management of Chronic Sinusitis Due to Cystic Fibrosis Arch Otolaryngol Head Neck Surg, May 1, 2000; 126(5): 581 - 583. [Abstract] [Full Text] [PDF]